Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials

@article{Reeves2014RenalSP,
  title={Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials},
  author={I. Reeves and M. Fisher and S. Kegg and J. Arribas and L. Dau and W. Garner and I. Walker and T. Nguyen},
  journal={Journal of the International AIDS Society},
  year={2014},
  volume={17}
}
  • I. Reeves, M. Fisher, +5 authors T. Nguyen
  • Published 2014
  • Medicine
  • Journal of the International AIDS Society
  • Cobicistat, a component of stribild (STB), is known to inhibit renal creatinine secretion. A detailed analysis of the renal safety profile of STB in two Phase 3b switch studies of virologically‐suppressed individuals on stable therapy: STRATEGY(S)‐PI (STB vs a RTV‐boosted protease inhibitor [PI] with emtricitabine and tenofovir DF [FTC/TDF]); and STRATEGY(S)‐NNRTI (STB versus a non‐nucleoside reverse transcriptase inhibitor [NNRTI] with FTC/TDF) is herein described. 
    2 Citations